Understanding diabetes in patients with HIV/AIDS

Diabetology and Metabolic Syndrome

Volumn 3, Issue 1, 2011, Pages

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Agrawal, Navneet ^b   Unnikrishnan, Ag ^c  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

^b DOTC   (India)

^c AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; APPETITE STIMULANT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INDINAVIR; INSULIN; INSULIN ASPART; INSULIN LISPRO; LAMIVUDINE; LOPINAVIR; MEGESTEROL ACETATE; METFORMIN; NELFINAVIR; ORAL ANTIDIABETIC AGENT; PENTAMIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; REPAGLINIDE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPREHENSION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG WITHDRAWAL; FATTY ACID BLOOD LEVEL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGLYCEMIA; IMMUNE DEFICIENCY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIPODYSTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSYCHOSOCIAL ADJUSTMENT TO ILLNESS SCALE; PSYCHOSOCIAL CARE; REVIEW; SCREENING; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78651365458     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-3-2     Document Type: Review

References (51)

1. HIV Data, http://www.unaids.org/en/KnowledgeCentre/HIVData/default.asp Accessed 22 December, 2010.
2. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization. F Young JA Critchley LK Johnstone LC Unwin, Globalization and Health 2009 5 9 10.1186/1744-8603-5-9 19751503
3. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Federation and Adult treatment Panel III criteria. K Samaras H Wand M Law S Emery D Cooper A Carr, Diabetes Care 2007 30 1 113 115 10.2337/dc06-1075 17192343
4. Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D). S De Wit CA Sabin R Weber SW Worm P Reiss C Cazanave W El-Sadr Ad'A Monforte E Fontas MG Law N Friss-Moller A Phillips, Study Diabetes Care 2008 31 6 1224 9 10.2337/dc07-2013
5. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. CJ Fichtenbaum CM Hadigan DP Kotler, et al. IAPAC Monthly 2005 38 46 15971353
6. Lipodystrophy syndrome: the morphologic and metabolic effects of antiretroviral therapy in HIV infection. A Norris HM Dreher, J Assoc of Nurses in AIDS care 2004 15 46 46 10.1177/1055329004271187
7. HIV and HIV Treatment: effects on fats, glucose and lipids. E Gkarnia-Klotsas AE Klotsas, BMB 2007 1093 1 20
8. Defining the metabolic syndrome construct: multi-ethnic study of atherosclerosis cross-sectional analysis. D Vaidya M Szklo K Liu PJ Schreiner AG Bertoni P Ouyang, Diabetes Care 2007 30 5 2086 2090 10.2337/dc07-0147 17485573
9. Metabolic syndrome in HIV-infected patients from an urban, Midwestern US outpatient population. K Mondy ET Oovertan J Grubb, et al. Clin Infec Dis 2007 44 726 734 10.1086/511679
10. HIV therapy and diabetes risk. S Dagogo-Jack, Diabetes Care 2008 31 6 1267 1268 10.2337/dc08-0459 18509145
11. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy. D Takarabe Y Rokukawa Y Takahashi A Goto M Takaichi M Okamoto T Tsujimoto H Noto M Kishimoto Y Kaburagi K Yasuda R Yamamoto-Honda K Tsukada M Honda K Teruya H Kajio Y Kikuchi S Oka M Noda, Journal of Clin Endocrinol Metab 2010 95 8 4056 4060 10.1210/jc.2010-0055
12. Disorders of glucose metabolism in the context of human immunodeficiency virus infection. R Larsson B Capili M Eckert-Norton JP Colagreco JK Anastasi, J AANP 2006 18 92 103
13. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. SH Mehta FL Brancati MS Sulkowski M Szklo DL Thomas, Ann Intern Med 2001 133 592 599
14. Association of chronic hepatitis C virus infection and Diabetes mellitus in Korean patients. JK Ryu SB Lee SJ Hong S Lee, Korean J Intern Med 2001 16 18 23 11417300
15. Effects of GH replacement on endothelial function and large artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. JC Smith LM Evans I Wilkinson, et al. Clinical Endocrinology 2002 56 493 501 10.1046/j.1365-2265.2002.01514.x 11966742
16. Serum adipocytokines are related to lipodystrophy and metabolic disorder in HIV-infected men under antiretroviral therapy. C Vigouroux M Maachi TH Nguyen, et al. AIDS 2003 17 1503 1511 10.1097/00002030-200307040-00011 12824788
17. HIV Outpatient Study Investigators: Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. FJ Palella Jr KM Delaney AC Moorman MO Loveless J Fuhrer GA Satten DJ Achman SD Holmberg, N Engl J Med 1998 338 853 860 10.1056/NEJM199803263381301 9516219
18. New drugs and diabetes risk: antipsychotic and antiretroviral agents. S Dagogo-Jack, Clinical diabetes Fonseca VA, ED. Philadelphia, Saunders 2006 569 581 full-text
19. Antiretroviral Therapy and the prevalence and incidence of diabetes in a multicenter AIDS Cohort study. TT Brown SR Cole LA Kingsley FJ Palella SA Riddler BR Visscher JB Margoluck AS Dobs, Arch Interm Med 2005 165 1179 1184 10.1001/archinte.165.10.1179
20. Mechanisms for the deterioration in glucose tolerance associated with protease inhibitor regumem. HJ Woerle PR Marivz C Meyer RC Reichman PFAEM JM Dostou SL Welle JE Gerich, Diabetes 2003 52 918 925 10.2337/diabetes.52.4.918 12663461
21. The effects of HIV Protease inhibitors on carbohydrate and lipid metabolism. GA Lee M Rao C Greenfeld, Curr Infect Dis Resp 2004 6 471 482 10.1007/s11908-004-0067-5
22. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. A Fleishman S Johnsen DM Systrom, et al. Am J Physiol Endocrinol Metab 2007 292 1666 E673 10.1152/ajpendo.00550.2006 17284576
23. Diabetes following pentamidine-induced hypoglycemia in humans. PH Bouchard P Sai G Reach I Caubarrere D Ganeval R Assa, Diabetes 1982 31 40 45 10.2337/diabetes.31.1.40 6759211
24. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. H Waskin JK Stehr-Green CG Helmick FR Sattler, JAMA 1988 260 345 347 10.1001/jama.260.3.345 3259989
25. Pentamidine: a review. M Sands MA Kron RB Borown, Review of Infectious Diseases 1985 7 5 625 634
26. The acquired immunodeficiency syndrome: an update. AS Fauci moderator, Ann Intern Med 1985 102 800 13 2986509
27. Diabetes mellitus induced by megesterol acetate in patients with AIDS and cachexia. K Henry S Rathgaber C Sullivan K McCabe, Ann Intern Med 1992 116 53 54 1727096
28. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. M Schambelan CA Benson A Carr, et al. J Acquir Immune Defic Syndr 2002 33 257 275
29. JD Lundgren M Battegay G Behrens, et al. EACS Executive Committee European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV Med 2008 9 72 81
30. NCCAM Research Report: Treating Type 2 Diabetes with Dietary Supplements. United State Department of health and Human Services, Bethesda Maryland: 2005; National Institute of Health
31. Management of the metabolic syndrome in patients with human immunodeficency virus. K Feigenbaum L Longstaff, The Diabetes Educator 2010 36 3 457 64 10.1177/0145721710363619 20348287
32. Effects of lifestyle modification programs in HIV-infected patients with metabolic syndrome. KV Fitch EJ Anderson JL Hubbard, et al. AIDS 2006 20 1843 1850 10.1097/01.aids.0000244203.95758.db 16954725
33. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. FP Robinson LT Quinn JH Rimmer, Bio Res Nurs 2007 3 177 185 10.1177/1099800406295520
34. Exercise treatment for HIV associated metabolic and anthropomorphic complications. KE Yarasheski R Roubenoff, Exercise Sport Sci Rev 2001 29 170 174 10.1097/00003677-200110000-00007
35. Reuters Thomson Micromedex, http://www.thomsonhc.com/home/dispatch Accessed December 22, 2010.
36. Motivational interviewing: The WATER approach. S Kalra B Kalra A Sharma M Sirka, Endocrine Journal 2010 57 391
37. Coping skills training: The AEIOU approach. S Kalra B Kalra A Sharma M Sirka, Endocrine Journal 2010 57 391
38. Clinician Summary Guide: Comparing Oral Medications for Adults with Type 2 Diabetes. Agency for Healthcare Research and Quality, Rockville, Maryland: 2007; Agency for Healthcare Research of Quality
39. Hyperglycemia in HIV/AIDS. GR Spollett, Diabetes Spectrum 2006 19 163 166 10.2337/diaspect.19.3.163
40. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. R Kohli A Shevitz S Gorbach C Wanke, HIV Medicine 2007 8 420 426 10.1111/j.1468-1293.2007.00488.x 17760733
41. No effect of rosiglitazone for HIV-1 lipoatrophy: a randomised, double-blind, placebo-controlled trial. A Carr C Workman D Carey G Rogers A Martin D Baker H Wand M Law K Samaras S Emery DA Cooper the Rosey Investigators, Lancet 2004 363 429 438 10.1016/S0140-6736(04)15489-5 14962523
42. Efficacy and safety of sitagliptin in the treatment of type 2 diabetes. Clinical Medicine. R Gadsby, Therapeutics 2009 1 53 62
43. Liraglutide-A Novel GLP-1 Analogue. S Kalra B Kalra A Sharma, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2009 3 200 204
44. Persons with type 2 diabetes and co-morbid active tuberculosis should be treated with insulin. PV Rao, Int J Diab Dev Countries 1999 19 79 86
45. Statement by an AACE/ACE Consensus Panel on type 2 diabetes mellitus. An algorithm for glycemic control. HW Rodbard PS Jelleinger JA Davidson, et al. Endocrine Practice 2009 15 540 559 19858063
46. Ketonuria and ketonemia in type 2 diabetes mellitus patients attending an Indian endocrine clinic. S Kalra B Kalra A Sharma, Ind J Endocr & Metab 2007 11 7 10
47. OPD management of ketosis in pregnancy: aspart vs. regular insulin. S Kalra B Kalra G Nanda, Diabetic Medicine 2006 23 504
48. S Kalra, Walking the tightrope in critical care: role of rapid-acting analogue insulin Jay Pee Bros, New Delhi, Agarwal AK, 2009 19 Part I 394 388 Medicine Update
49. Dosage frequency of premixed aspart insulin: clinical correlates of three-dose. S Kalra B Kalra A Sharma B Chhabra, Diabetes 2008 57 570
50. CD4+ count-guided interruption of antiretroviral treatment. WM El-Sadr JD Lundgren JD Neaton, et al. N Engl J Med 2006 355 2283 2296 10.1056/NEJMoa062360 17135583
51. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. J Ananworanich A Gayet-Ageron M Le Braz, et al. The Lancet 2006 368 459 465 10.1016/S0140-6736(06)69153-8